CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
13.175
0.68%
Market Trading Hours* (UTC) Opens on Thursday at 07:00

Mon - Fri: 07:00 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.070
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.022102 %
Charges from full value of position ($-4.20)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.022102%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000121 %
Charges from full value of position ($-0.02)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000121%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange Germany
Commission on trade 0%

*Information provided by Capital.com

Evotec SE ESG Risk Ratings

High Medium Low Negligible

‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

More ESG coverage

Key Stats
Prev. Close* 13.265
Open* 13.065
1-Year Change* -31.49%
Day's Range* 12.995 - 13.285
52 wk Range 14.10-24.44
Average Volume (10 days) 1.22M
Average Volume (3 months) 12.25M
Market Cap 2.58B
P/E Ratio -100.00K
Shares Outstanding 176.94M
Revenue 820.80M
EPS -0.54
Dividend (Yield %) N/A
Beta 0.98
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 16, 2024 13.265 -0.170 -1.27% 13.435 13.545 13.135
Apr 15, 2024 13.770 0.190 1.40% 13.580 14.010 13.525
Apr 12, 2024 13.730 -0.050 -0.36% 13.780 14.300 13.600
Apr 11, 2024 13.255 -0.040 -0.30% 13.295 13.605 12.735
Apr 10, 2024 13.465 -0.935 -6.49% 14.400 14.510 13.385
Apr 9, 2024 14.390 0.090 0.63% 14.300 14.550 14.270
Apr 8, 2024 14.480 0.600 4.32% 13.880 14.590 13.810
Apr 5, 2024 13.850 -0.050 -0.36% 13.900 13.910 13.650
Apr 4, 2024 14.070 0.040 0.29% 14.030 14.160 13.790
Apr 3, 2024 14.020 0.010 0.07% 14.010 14.100 13.650
Apr 2, 2024 14.030 -0.280 -1.96% 14.310 14.370 13.930
Mar 28, 2024 14.500 0.205 1.43% 14.295 14.730 14.100
Mar 27, 2024 14.300 0.620 4.53% 13.680 14.420 13.680
Mar 26, 2024 13.770 0.350 2.61% 13.420 13.915 13.270
Mar 25, 2024 13.505 -0.075 -0.55% 13.580 13.620 13.355
Mar 22, 2024 13.650 0.440 3.33% 13.210 13.655 13.210
Mar 21, 2024 13.365 -0.460 -3.33% 13.825 14.000 13.185
Mar 20, 2024 13.600 0.055 0.41% 13.545 13.685 13.395
Mar 19, 2024 13.400 0.355 2.72% 13.045 13.440 12.905
Mar 18, 2024 13.055 0.395 3.12% 12.660 13.305 12.660

Evotec AG Events

Time (UTC) Country Event
Wednesday, April 24, 2024

Time (UTC)

05:00

Country

DE

Event

Full Year 2023 Evotec SE Earnings Release
Full Year 2023 Evotec SE Earnings Release

Forecast

-

Previous

-

Time (UTC)

10:59

Country

DE

Event

Full Year 2023 Evotec SE Earnings Call
Full Year 2023 Evotec SE Earnings Call

Forecast

-

Previous

-
Wednesday, May 15, 2024

Time (UTC)

10:59

Country

DE

Event

Evotec SE at Bank of America Health Care Conference
Evotec SE at Bank of America Health Care Conference

Forecast

-

Previous

-
Wednesday, May 22, 2024

Time (UTC)

05:00

Country

DE

Event

Q1 2024 Evotec SE Earnings Release
Q1 2024 Evotec SE Earnings Release

Forecast

-

Previous

-

Time (UTC)

10:59

Country

DE

Event

Q1 2024 Evotec SE Earnings Call
Q1 2024 Evotec SE Earnings Call

Forecast

-

Previous

-
Monday, June 10, 2024

Time (UTC)

10:59

Country

DE

Event

Evotec SE Annual Shareholders Meeting
Evotec SE Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, June 19, 2024

Time (UTC)

10:59

Country

DE

Event

Evotec SE Annual Shareholders Meeting
Evotec SE Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 751.448 618.034 500.924 446.437 375.405
Revenue 751.448 618.034 500.924 446.437 375.405
Cost of Revenue, Total 577.383 466.491 375.181 313.546 263.389
Gross Profit 174.065 151.543 125.743 132.891 112.016
Total Operating Expense 724.824 588.901 452.368 383.843 297.942
Selling/General/Admin. Expenses, Total 156.19 105.445 77.205 66.546 57.012
Research & Development 76.642 72.2 63.945 58.432 35.619
Unusual Expense (Income) -5.774 12.546 3.244 11.919 -11.036
Other Operating Expenses, Total -79.617 -67.781 -67.207 -66.6 -47.042
Operating Income 26.624 29.133 48.556 62.594 77.463
Interest Income (Expense), Net Non-Operating -179.854 208.106 -22.925 -6.102 -5.602
Other, Net -0.727 -0.259 0.209 0.07 0.138
Net Income Before Taxes -153.957 236.98 25.84 56.562 71.999
Net Income After Taxes -175.655 215.51 6.278 37.228 84.056
Minority Interest 0 0 0 0.844 0.116
Net Income Before Extra. Items -175.655 215.51 6.278 38.072 84.172
Net Income -175.655 215.51 6.278 38.072 84.172
Income Available to Common Excl. Extra. Items -175.655 215.51 6.278 38.072 84.172
Income Available to Common Incl. Extra. Items -175.655 215.51 6.278 38.072 84.172
Diluted Net Income -175.655 215.51 6.278 38.072 84.172
Diluted Weighted Average Shares 176.674 166.406 153.752 149.726 147.482
Diluted EPS Excluding Extraordinary Items -0.99423 1.29509 0.04083 0.25428 0.57073
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -1.01547 1.36365 0.05455 0.30667 0.52209
Dilution Adjustment 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 170.279 213.556 240.689 173.884 172.203
Revenue 170.279 213.556 240.689 173.884 172.203
Cost of Revenue, Total 123.956 160.319 158.233 145.464 141.308
Gross Profit 46.323 53.237 82.456 28.42 30.895
Total Operating Expense 206.567 201.041 197.229 187.413 175.973
Selling/General/Admin. Expenses, Total 45.609 42.583 46.332 42.462 35.83
Research & Development 12.377 18.486 21.322 18.482 18.725
Other Operating Expenses, Total 24.625 -20.347 -22.884 -18.995 -19.89
Operating Income -36.288 12.515 43.46 -13.529 -3.77
Interest Income (Expense), Net Non-Operating 5.261 -6.203 -60.362 -29.806 -20.131
Other, Net 10.59 -12.527 -0.622 -0.029 -0.435
Net Income Before Taxes -20.437 -6.215 -17.524 -43.364 -24.336
Net Income After Taxes -14.929 -13.898 -27.201 -47.275 -27.937
Net Income Before Extra. Items -14.929 -13.898 -27.201 -47.275 -27.937
Net Income -14.929 -13.898 -27.201 -47.275 -27.937
Income Available to Common Excl. Extra. Items -14.929 -13.899 -27.201 -47.275 -27.937
Income Available to Common Incl. Extra. Items -14.929 -13.899 -27.201 -47.275 -27.937
Diluted Net Income -14.929 -13.899 -27.201 -47.275 -27.937
Diluted Weighted Average Shares 176.936 176.936 176.589 176.703 176.703
Diluted EPS Excluding Extraordinary Items -0.08438 -0.07855 -0.15404 -0.26754 -0.1581
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -0.08438 -0.07855 -0.17529 -0.26754 -0.1581
Unusual Expense (Income) -5.774 0 0
Minority Interest 0
Total Adjustments to Net Income -0.001
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1073.67 1100.94 658.844 469.53 249.769
Cash and Short Term Investments 729.983 858.498 492.634 321.662 149.879
Cash & Equivalents 415.155 699.326 422.58 277.034 109.055
Short Term Investments 314.828 159.172 70.054 44.628 40.824
Total Receivables, Net 256.737 176.754 122.221 117.844 74.772
Accounts Receivable - Trade, Net 199.169 150.692 91.612 93.702 58.851
Total Inventory 29.825 25.793 13.585 10.749 5.66
Prepaid Expenses 40.178 19.21 9.258 9.166 8.451
Other Current Assets, Total 16.948 20.685 21.146 10.109 11.007
Total Assets 2257.25 2235.16 1462.34 1180.91 771.883
Property/Plant/Equipment, Total - Net 650.201 484.597 337.297 239.229 90.519
Property/Plant/Equipment, Total - Gross 920.81 686.086 481.879 350.415 164.143
Accumulated Depreciation, Total -270.609 -201.489 -144.582 -111.186 -73.624
Goodwill, Net 274.819 257.569 247.37 255.919 220.791
Intangibles, Net 23.819 30.851 98.036 116.994 122.989
Long Term Investments 150.332 287.009 59.021 41.252 28.99
Note Receivable - Long Term 70.293 55.966 36.485 22.718 14.601
Other Long Term Assets, Total 14.112 18.229 25.284 35.27 44.224
Total Current Liabilities 337.706 324.516 208.459 178.955 196.275
Accounts Payable 97.277 72.598 42.549 31.319 31.137
Accrued Expenses 47.49 33.983 34.728 29.174 25.67
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 16.381 50.609 30.008 20.731 56.919
Other Current Liabilities, Total 176.558 167.326 101.174 97.731 82.549
Total Liabilities 1070.06 857.476 737.881 703.883 347.879
Total Long Term Debt 490.293 462.308 461.957 442.368 57.546
Long Term Debt 328.295 326.344 331.019 324.886 54.68
Capital Lease Obligations 161.998 135.964 130.938 117.482 2.866
Deferred Income Tax 18.524 17.688 20.399 21.199 21.517
Minority Interest 0 0 0 0 0.876
Other Liabilities, Total 223.54 52.964 47.066 61.361 71.665
Total Equity 1187.18 1377.69 724.456 477.029 424.004
Common Stock 176.953 176.608 163.915 150.903 149.063
Additional Paid-In Capital 1440.01 1430.14 1030.7 786.865 783.154
Retained Earnings (Accumulated Deficit) -392.377 -216.421 -432.639 -441.177 -481.013
Unrealized Gain (Loss) -21.113 3.053 4.26 4.565 6.002
Other Equity, Total -16.289 -15.691 -41.782 -24.127 -33.202
Total Liabilities & Shareholders’ Equity 2257.25 2235.16 1462.34 1180.91 771.883
Total Common Shares Outstanding 176.703 176.358 163.665 150.653 148.813
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 939.198 1026.45 1073.67 1095.82
Cash and Short Term Investments 619.18 632.973 729.983 828.795
Cash & Equivalents 499.366 459.752 415.155 463.913
Short Term Investments 119.814 173.221 314.828 364.882
Total Receivables, Net 219.371 291.301 256.737 187.997
Accounts Receivable - Trade, Net 161.105 228.955 199.169 140.631
Total Inventory 31.906 32.612 29.825 30.874
Prepaid Expenses 68.741 69.563 57.126 48.15
Total Assets 2254.51 2301.22 2257.25 2262.66
Property/Plant/Equipment, Total - Net 763.899 721.136 650.201 600.499
Goodwill, Net 274.819 278.417
Intangibles, Net 291.055 292.612 23.819 25.736
Long Term Investments 151.62 160.842 150.332 189.245
Note Receivable - Long Term 98.685 88.8 70.293 56.911
Other Long Term Assets, Total 10.052 11.382 14.112 16.039
Total Current Liabilities 434.045 488.107 337.706 340.802
Accounts Payable 96.774 106.038 97.277 83.965
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 144.287 151.638 16.381 14.108
Other Current Liabilities, Total 192.984 230.431 224.048 242.729
Total Liabilities 1113.69 1126.93 1070.06 1034.14
Total Long Term Debt 444.455 382.509 490.293 477.984
Long Term Debt 444.455 382.509 328.295 326.776
Capital Lease Obligations 161.998 151.208
Deferred Income Tax 18.603 19.13 18.524 17.179
Other Liabilities, Total 216.587 237.188 223.54 198.173
Total Equity 1140.82 1174.29 1187.18 1228.53
Common Stock 177.186 177.186 176.953 176.953
Additional Paid-In Capital 1446.47 1445.36 1440.01 1437.55
Retained Earnings (Accumulated Deficit) -482.836 -448.256 -392.377 -364.631
Other Equity, Total -16.289 -21.348
Total Liabilities & Shareholders’ Equity 2254.51 2301.22 2257.25 2262.66
Total Common Shares Outstanding 176.936 176.936 176.703 176.703
Unrealized Gain (Loss) -21.113
Minority Interest 0 0 0 0
Other Current Assets, Total 0.001
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -175.655 215.51 6.252 37.228 84.056
Cash From Operating Activities 203.106 122.237 44.721 42.216 156.24
Cash From Operating Activities 72.677 55.596 42.122 36.456 19.288
Amortization 8.982 12.012 13.936 12.349 12.005
Deferred Taxes 7.722 5.066 7.49 6.706 -26.117
Non-Cash Items 195.391 -165.371 23.865 24.342 0.364
Cash Taxes Paid 18.5 -6.028 9.796 2.417 3.596
Cash Interest Paid 9.798 5.429 3.465 4.49 2.279
Changes in Working Capital 93.989 -0.576 -48.944 -74.865 66.644
Cash From Investing Activities -415.823 -243.855 -155.089 -86.634 -39.13
Capital Expenditures -181.354 -118.943 -99.072 -31.905 -27.867
Other Investing Cash Flow Items, Total -234.469 -124.912 -56.017 -54.729 -11.263
Cash From Financing Activities -52.414 398.43 246.409 211.263 -77.764
Financing Cash Flow Items
Issuance (Retirement) of Stock, Net 0.699 404.322 251.564 1.901 1.578
Issuance (Retirement) of Debt, Net -53.113 -5.892 -5.155 209.362 -79.342
Foreign Exchange Effects -19.04 -0.066 9.505 1.134 2.692
Net Change in Cash -284.171 276.746 145.546 167.979 42.038
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Net income/Starting Line -175.655 -148.454 -101.179 -73.242 215.51
Cash From Operating Activities 203.106 236.633 240.607 63.618 122.237
Changes in Working Capital 378.761 385.087 341.786 136.86 -93.273
Cash From Investing Activities -415.823 -435.034 -206.857 -95.732 -243.855
Capital Expenditures -181.354 -157.21 -81.371 -42.921 -118.943
Other Investing Cash Flow Items, Total -234.469 -277.824 -125.486 -52.811 -124.912
Cash From Financing Activities -52.414 -50.454 -45.805 -5.279 398.43
Issuance (Retirement) of Stock, Net 0.699 0.355 0.7 0.345 404.322
Issuance (Retirement) of Debt, Net -53.113 -50.809 -46.505 -5.624 -5.892
Foreign Exchange Effects -19.04 13.442 9.721 -1.445 -0.066
Net Change in Cash -284.171 -235.413 -2.334 -38.838 276.746

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Evotec Company profile

About Evotec SE

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Evotec SE revenues increased 20% to EUR431M. Net income increased from EUR5.8M to EUR247M. Revenues reflect EVT Execute segment increase of 22% to EUR329M, EVT Innovate segment increase of 36% to EUR101.9M, United States segment increase of 32% to EUR142.9M, Others segment increase of 30% to EUR47.5M, United Kingdom segment increase of 8% to EUR47.2M.

Industry: Biotechnology & Medical Research (NEC)

Essener Bogen 7
HAMBURG
HAMBURG 22419
DE

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

ETH/USD

3,004.32 Price
-2.310% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

17,507.60 Price
-1.250% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

2,372.05 Price
-0.450% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.40

BTC/USD

61,404.00 Price
-2.720% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading